Gilead Sciences Inc., of Foster City, Calif., reported that the European Commission granted marketing authorization for Sovaldi (sofosbuvir) 400 mg tablets as a once-daily oral treatment of chronic hepatitis C in adults, in combination with ribavirin and pegylated interferon alpha.